Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Corcept Therapeutics Inc CORT

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.


NDAQ:CORT - Post by User

Post by krbcanon Mar 16, 2017 11:43am
218 Views
Post# 25988159

Patrick G. Enright Sells 600,000 Shares

Patrick G. Enright Sells 600,000 Shares
https://www.chaffeybreeze.com/2017/03/15/patrick-g-enright-sells-600000-shares-of-corcept-therapeutics-incorporated-cort-stock.html

Director Patrick G. Enright sold 600,000 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The stock was sold at an average price of $10.15, for a total value of $6,090,000.00. Following the completion of the transaction, the director now owns 204,210 shares of the company’s stock, valued at $2,072,731.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) traded up 2.82% on Wednesday, hitting $10.21. The stock had a trading volume of 1,170,543 shares. Corcept Therapeutics Incorporated has a 52-week low of $3.85 and a 52-week high of $11.40. The firm has a market cap of $1.15 billion, a PE ratio of 145.86 and a beta of 1.72. The firm’s 50-day moving average price is $8.55 and its 200 day moving average price is $7.67.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Monday, March 6th. The company reported $0.04 EPS for the quarter, meeting the consensus estimate of $0.04. Corcept Therapeutics had a net margin of 6.21% and a return on equity of 28.11%. On average, equities research analysts predict that Corcept Therapeutics Incorporated will post $0.26 EPS for the current year.

<< Previous
Bullboard Posts